KindredBio Board of Directors

Denise Bevers

Denise Bevers

As co-founder of KindredBio, Denise Bevers served as President & Chief Operating Officer until July 2020. Ms. Bevers has over 30 years of drug development experience and a proven track record of building successful teams. She is the Chief Operating Officer of DTx Pharma, a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease. Previously, she was President and Founding Partner of SD Scientific, a full-service medical affairs and communications company, and held management positions at Elan Pharmaceuticals, SkyePharma, Quintiles, and Scripps Clinic and Research Foundation. When Ms. Bevers is not spending time with her four-legged children, she and her husband are passionate supporters of theatre, both locally and as Broadway investors. She is a board member of Hilltop Bio, a veterinary regenerative medicine company, and a proud member of the executive team of La Jolla Playhouse’s board of trustees.

Nanxi Liu

Nanxi Liu

Nanxi Liu is CEO and Co-Founder of Enplug, a digital display software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune’s 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that enable vaccines and other biologics to be stored without refrigeration. Ms. Liu serves on the Board of CarParts.com, on the Board of Advisors for Covington Capital Management, and on the California Department of Motor Vehicles’ New Motor Vehicle Board. She received a BS in Business Administration and BA in Political Economy from UC Berkeley.

Ervin Veszprémi

Ervin Veszprémi

Ervin Veszprémi previously served as the Vice President and Global Head of Marketing at Novartis Animal Health, one of the largest veterinary companies in the world. Prior to that, he was Country Head of Ciba-Geigy Animal Health Spain. He has more than 30 years’ experience in the pharmaceutical industry, including 15 in the animal health sector. Mr. Veszprémi is the former Chief Executive Officer of Medichem, a leading Active Pharmaceutical Product manufacturer, and Invent Farma, a vertically integrated generics company. He holds a physiology degree from the University of British Columbia and has studied management at Harvard Business School and Stanford University.

Raymond Townsend, PharmD

Raymond Townsend, PharmD

Raymond Townsend is a pioneer in the pharmacoeconomics field. He was formerly the Worldwide Director and Vice President, Outcomes, Epidemiology and Policy Research at Glaxo (now GlaxoSmithKline). He also served as Senior Vice President, Pharmacoeconomic & Epidemiology Outcomes Research, at Elan Pharmaceuticals, Inc. From 2001 until his retirement in 2017, Dr. Townsend served as the President of Wasatch Health Outcomes, Inc., his personal consulting firm engaged in providing support for pharmaceutical product development, pricing and commercialization. Dr. Townsend earned a B.A. in Economics at California State University and his Doctor of Pharmacy degree from the University of California, San Francisco.

Herbert D. Montgomery

Herbert D. Montgomery

Herbert D. Montgomery has extensive experience in finance, including having served as Chief Financial Officer of several public companies, and having taken three companies public. He was Vice Chairman and Chief Executive Officer of Lightpost Holdings, LLC. Prior to that, Mr. Montgomery was Executive Vice President, Chief Financial Officer, and Treasurer of Standard Media International; Senior Vice President, Chief Financial Officer and Treasurer of Cotelligent, Inc.; and Senior Vice President, Chief Financial Officer and Treasurer of Guy F. Atkinson; and has served as Financial Officer of high technology, product development and services companies for over 20 years. He holds a Master of Science degree in Management and a Bachelor of Science degree in Finance from California State University, Northridge. Mr. Montgomery was also previously Chairman of the Board and Director of The Institute for OneWorld Health; and a Board Director of Bank of San Clemente.

Joseph S. McCracken DVM, MS

Joseph S. McCracken DVM, MS

Joseph S. McCracken, D.V.M. was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for more than 9 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. He currently serves on the boards of Savara Pharmaceuticals, Regimmune Inc, Modalis Therapeutics, Lumos Pharmaceuticals and Neuropore Therapies, and he previously served as a Director of NexVet. Dr. McCracken holds a B.S. in Microbiology, an M.S. in Pharmacology, and a Doctor of Veterinary Medicine from The Ohio State University.

Lyndon Lien

Lyndon Lien

Lyndon Lien is an experienced biotech CEO, entrepreneur and investor. He is CEO and Co-Founder of Qinotto, a biopharmaceutical company discovering and developing therapeutics for neurological diseases. Previously, Dr. Lien was Operating Partner at Pivotal bioVenture Partners, a life sciences venture capital firm. He was also CEO and Co-Founder of Balance Therapeutics, a rare cognition and sleep disorder biopharmaceutical company which he led from early preclinical development through Phase 2 clinical trials. Dr. Lien previously served in various strategy, business development, and operating roles at Elan, J&J, and McKinsey. Dr. Lien received a PhD in Genetics and an AB from Harvard University, and an MBA from MIT Sloan School of Management.

Richard Chin, MD

Richard Chin, MD

Founder and Chief Executive Officer

Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.

Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw all of Genentech’s drug development programs except oncology products; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.